These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 16206354)

  • 41. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis.
    Recker R; Stakkestad JA; Chesnut CH; Christiansen C; Skag A; Hoiseth A; Ettinger M; Mahoney P; Schimmer RC; Delmas PD
    Bone; 2004 May; 34(5):890-9. PubMed ID: 15121021
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate.
    Blumentals WA; Harris ST; Cole RE; Huang L; Silverman SL
    Ann Pharmacother; 2009 Apr; 43(4):577-85. PubMed ID: 19318598
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
    Cosman F; Borges JL; Curiel MD
    Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA.
    Sambrook P; Cranney A; Adachi JD
    Curr Med Res Opin; 2010 Mar; 26(3):599-604. PubMed ID: 20055751
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: a review.
    Miller PD; Ward P; Pfister T; Leigh C; Body JJ
    Clin Exp Rheumatol; 2008; 26(6):1125-33. PubMed ID: 19210886
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Monthly ibandronate attachment to Mexican and Chilean women with osteoporosis, with or without a biofeedback strategy].
    García-Hernández P; Carranza-Lira S; Motta-Martínez E
    Ginecol Obstet Mex; 2010 Jun; 78(6):322-8. PubMed ID: 20939245
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ibandronate: a review of its use in the management of postmenopausal osteoporosis.
    Frampton JE; Perry CM
    Drugs; 2008; 68(18):2683-707. PubMed ID: 19093707
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ibandronate: A Review in Japanese Patients with Osteoporosis.
    Keating GM
    Drugs Aging; 2016 Apr; 33(4):295-303. PubMed ID: 26915075
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ibandronate treatment for osteoporosis: rationale, preclinical, and clinical development of extended dosing regimens.
    Epstein S
    Curr Osteoporos Rep; 2006 Mar; 4(1):14-20. PubMed ID: 16527003
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study.
    Greenspan S; Field-Munves E; Tonino R; Smith M; Petruschke R; Wang L; Yates J; de Papp AE; Palmisano J
    Mayo Clin Proc; 2002 Oct; 77(10):1044-52. PubMed ID: 12374248
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment.
    Derman R; Kohles JD; Babbitt A
    Clin Interv Aging; 2009; 4():357-65. PubMed ID: 19851511
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Ibandronate].
    Tobinai M
    Clin Calcium; 2011 Jan; 21(1):79-86. PubMed ID: 21187598
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bisphosphonates for prevention of postmenopausal osteoporosis.
    Ravn P
    Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Progression of efficacy with ibandronate: a paradigm for the development of new bisphosphonates.
    Zaidi M; Epstein S; Harris ST; Kohles JD; Chesnut CH
    Ann N Y Acad Sci; 2007 Nov; 1117():273-82. PubMed ID: 18056047
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oral ibandronate preserves trabecular microarchitecture: micro-computed tomography findings from the oral iBandronate Osteoporosis vertebral fracture trial in North America and Europe study.
    Recker RR; Ste-Marie LG; Langdahl B; Masanauskaite D; Ethgen D; Delmas PD
    J Clin Densitom; 2009; 12(1):71-6. PubMed ID: 19084450
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study.
    Ringe JD; Dorst A; Faber H; Ibach K; Sorenson F
    Osteoporos Int; 2003 Oct; 14(10):801-7. PubMed ID: 14610641
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment.
    Sebba AI
    Clin Ther; 2008 Mar; 30(3):443-52. PubMed ID: 18405784
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate.
    Bonnick SL; Silverman S; Tanner SB; Martens M; Bachmann G; Kohles JD; Civitelli R
    J Womens Health (Larchmt); 2009 Jul; 18(7):935-43. PubMed ID: 19563245
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.
    Ste-Marie LG; Brown JP; Beary JF; Matzkin E; Darbie LM; Burgio DE; Racewicz AJ
    Clin Ther; 2009 Feb; 31(2):272-85. PubMed ID: 19302900
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
    De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
    Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.